Skip to main content
. Author manuscript; available in PMC: 2016 Apr 15.
Published in final edited form as: Int J Cancer. 2014 Sep 29;136(8):1967–1975. doi: 10.1002/ijc.29225

Figure 3.

Figure 3

Tumors harbouring a PIK3CA mutation exhibit enhanced sensitivity to cabozantinib. (A) Comparison of tumor growth (TGII) in PIK3CA wild type and mutant CRC explants treated with cabozantinib at end of study. ** p < 0.01, TGII comparison between PIK3CA mutant (CRC020, 040, 098 and 162) vs. PIK3CA wild type explants. (B) The isogenic 123 PIK3CA wild type and 125 PIK3CA mutant cell line-derived tumor xenografts were treated with cabozantinib 30 mg/kg daily for 14 days. Tumors with a PIK3CA mutation had greater sensitivity to cabozantinib when compared to PIK3CA wild type. Mean n = 10 tumours per group; s.e.m ***, significance (*P<0.001) compared with vehicle-treated tumours; #, p < 0.05, comparison between PIK3CA wild type vs. mutated treated mice. (C) Graph comparing the TGII of the 123 PIK3CA wild type and 125 PIK3CA mutant cell line-derived tumor xenografts at the end of study. (D) Akt phosphorylation in 123 PIK3CA wild type and 125 PIK3CA mutant cell line-derived tumor xenografts. Baseline levels of Akt were increased in the mutant tumors when compared with wild type.